SCHEMBL17368809

SCHEMBL17368809

CCOC(=O)c1csc(C(=O)CCCCc2ccc(-c3ccccc3)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 3/20 0.61
MMP1 P03956 1/20 0.52
MMP13 P45452 1/20 0.52
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CES1 P23141 5/20 0.46
GAA P10253 2/20 0.45
LMNA P02545 1/20 0.44
DAGLA Q9Y4D2 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
HDAC2 Q92769 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1667463 0.93 PLA2G4A (0.62) PLA2G4ARAB9ANPC1SMN1; SMN2CES1
SCHEMBL22452269 0.91 PLA2G4A (0.54) PLA2G4AMMP1MMP13RAB9ANPC1
SCHEMBL12548644 0.89 CES1 (0.56) PLA2G4ACES1DAGLAHDAC2
SCHEMBL12548449 0.85 PLA2G4A (0.59) PLA2G4AMMP1MMP13CES1DAGLA
SCHEMBL1667502 0.83 ALDH1A1 (0.48) LMNAMEN1ALDH1A1MAPTKMT2A
SCHEMBL20662520 0.80 PLA2G4A (0.68) PLA2G4ARAB9ANPC1SMN1; SMN2GAA
SCHEMBL17368814 0.80 DAGLA (0.69) CES1DAGLA
SCHEMBL1667122 0.79 PLA2G4A (0.71) PLA2G4ARAB9ANPC1SMN1; SMN2GAA
SCHEMBL1667949 0.78 PLA2G4A (0.64) PLA2G4ACES1MAPT
SCHEMBL22452066 0.78 PLA2G4A (0.42) PLA2G4ACES1HDAC2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds AVEXXIN AS (NO) 2023-07-04 US disclosed
US-10259801-B2 Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds AVEXXIN AS (NO) 2019-04-16 US disclosed
US-20180105507-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2018-04-19 US disclosed
US-20180105507-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2018-04-19 US disclosed
US-20150376161-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2015-12-31 US disclosed
US-20150376161-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS AVEXXIN AS (NO) 2015-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376161-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS FOXO1, FOXO3, BCOR PLA2G4A 446/4885MMP1 3789/4885MMP13 1954/4885
US-20180105507-A1 ANTIIFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES ABD 2-OXOTHIOPHENES COMPOUNDS FOXO1, FOXO3, BCOR PLA2G4A 446/4885MMP1 3789/4885MMP13 1954/4885
US-10259801-B2 Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds OXER1, CCL2, IL6 PLA2G4A 589/4885MMP1 2773/4885MMP13 1157/4885
US-11691959-B2 Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds CASP1, IL1B, OXER1 PLA2G4A 1579/4885MMP1 978/4885MMP13 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.